JP2022508942A - 変異ワクシニア・ウイルスおよびその使用 - Google Patents

変異ワクシニア・ウイルスおよびその使用 Download PDF

Info

Publication number
JP2022508942A
JP2022508942A JP2021547043A JP2021547043A JP2022508942A JP 2022508942 A JP2022508942 A JP 2022508942A JP 2021547043 A JP2021547043 A JP 2021547043A JP 2021547043 A JP2021547043 A JP 2021547043A JP 2022508942 A JP2022508942 A JP 2022508942A
Authority
JP
Japan
Prior art keywords
vaccinia virus
amino acid
virion
seq
recombinant vaccinia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508942A5 (https=
Inventor
シャオトン ソン，
マリヤ ヴィスコブスカ，
メダグリア， マリア ルイーザ ゴメス
Original Assignee
アイセルキーレクス セラピューティクス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイセルキーレクス セラピューティクス エルエルシー filed Critical アイセルキーレクス セラピューティクス エルエルシー
Publication of JP2022508942A publication Critical patent/JP2022508942A/ja
Publication of JP2022508942A5 publication Critical patent/JP2022508942A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021547043A 2018-10-22 2019-10-21 変異ワクシニア・ウイルスおよびその使用 Pending JP2022508942A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862749102P 2018-10-22 2018-10-22
US62/749,102 2018-10-22
US201962912344P 2019-10-08 2019-10-08
US62/912,344 2019-10-08
PCT/US2019/057134 WO2020086423A1 (en) 2018-10-22 2019-10-21 Mutant vaccinia viruses and use thereof

Publications (2)

Publication Number Publication Date
JP2022508942A true JP2022508942A (ja) 2022-01-19
JP2022508942A5 JP2022508942A5 (https=) 2022-10-31

Family

ID=70331869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547043A Pending JP2022508942A (ja) 2018-10-22 2019-10-21 変異ワクシニア・ウイルスおよびその使用

Country Status (10)

Country Link
US (1) US20210388388A1 (https=)
EP (1) EP3870217A4 (https=)
JP (1) JP2022508942A (https=)
KR (1) KR20210108944A (https=)
CN (1) CN113347993A (https=)
AU (1) AU2019367965A1 (https=)
CA (1) CA3117378A1 (https=)
IL (1) IL282509A (https=)
MX (1) MX2021004403A (https=)
WO (1) WO2020086423A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525454A (ja) * 2022-06-29 2025-08-05 シルラジェン，インコーポレイテッド Ｃｄ５５およびｃｄ５９を同時発現する抗癌ウイルス

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CN116615442A (zh) * 2020-09-08 2023-08-18 优特力克斯有限公司 程序性细胞死亡1多肽变体
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
US20240067936A1 (en) * 2021-02-26 2024-02-29 Sillajen, Inc. Oncolytic virus and uses thereof
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CN113322280A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN113481241A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除h3l基因的重组痘苗病毒载体
CN113322279A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种敲除d8l基因的重组痘苗病毒载体
CN113481240A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除l1r基因的重组痘苗病毒载体
CN114058645A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058643A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058644A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114369587B (zh) * 2021-12-25 2024-03-15 苏州瀚源新酶生物科技有限公司 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用
CN116179654B (zh) * 2022-12-30 2023-09-15 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用
CN116990507B (zh) * 2023-06-29 2025-07-08 深圳市新产业生物医学工程股份有限公司 一种用于猴痘病毒感染的早期筛查的方法
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002017370A (ja) * 2000-07-07 2002-01-22 Japan Science & Technology Corp 遺伝子組換えワクシニアウイルスワクチン
JP2002330774A (ja) * 2000-11-07 2002-11-19 Transgene Sa 標的化感染特異性を有するポックスウイルス
WO2009026456A2 (en) * 2007-08-21 2009-02-26 University Of Massachusetts Poxvirus methods and compositions
WO2009048839A2 (en) * 2007-10-10 2009-04-16 Kyowa Hakko Kirin Co., Ltd. Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
JP2015506372A (ja) * 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
WO2018002131A1 (en) * 2016-06-28 2018-01-04 Universität Ulm Complement inhibitors and uses thereof
WO2018032057A1 (en) * 2016-08-19 2018-02-22 Sementis Limited Viral vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
IN2012DN02692A (https=) * 2009-11-05 2015-09-04 Ct Molecular Med & Immunology
FI20115914L (fi) * 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002017370A (ja) * 2000-07-07 2002-01-22 Japan Science & Technology Corp 遺伝子組換えワクシニアウイルスワクチン
JP2002330774A (ja) * 2000-11-07 2002-11-19 Transgene Sa 標的化感染特異性を有するポックスウイルス
WO2009026456A2 (en) * 2007-08-21 2009-02-26 University Of Massachusetts Poxvirus methods and compositions
WO2009048839A2 (en) * 2007-10-10 2009-04-16 Kyowa Hakko Kirin Co., Ltd. Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
JP2015506372A (ja) * 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
WO2018002131A1 (en) * 2016-06-28 2018-01-04 Universität Ulm Complement inhibitors and uses thereof
WO2018032057A1 (en) * 2016-08-19 2018-02-22 Sementis Limited Viral vaccines

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN VIROLOGY, vol. 2012, JPN6023043454, 2012, pages 805629, ISSN: 0005324630 *
J BIOTECHNOL., vol. 92, no. 2, JPN7023003952, 28 December 2001 (2001-12-28), pages 159 - 168, ISSN: 0005178036 *
JOURNAL OF VIROLOGY, vol. 81, no. 4, JPN6023043452, 2007, pages 1680 - 1689, ISSN: 0005324632 *
LEUKEMIA, vol. 31, no. 8, JPN7023003951, August 2017 (2017-08-01), pages 1743 - 1751, ISSN: 0005178037 *
MOLECULAR THERAPY, vol. 20, no. 9, JPN6023043453, 2012, pages 1699 - 1712, ISSN: 0005324631 *
MOLECULAR THERAPY, vol. 22, no. 1, JPN6023043449, 2014, pages 102 - 111, ISSN: 0005324635 *
NAT. REV. GENET., vol. 15, no. 7, JPN6023043451, 2014, pages 445 - 451, ISSN: 0005324633 *
PNAS, vol. 95, JPN6023043450, 1998, pages 7544 - 7549, ISSN: 0005324634 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525454A (ja) * 2022-06-29 2025-08-05 シルラジェン，インコーポレイテッド Ｃｄ５５およびｃｄ５９を同時発現する抗癌ウイルス

Also Published As

Publication number Publication date
CA3117378A1 (en) 2020-04-30
EP3870217A4 (en) 2022-08-31
IL282509A (en) 2021-06-30
WO2020086423A1 (en) 2020-04-30
US20210388388A1 (en) 2021-12-16
EP3870217A1 (en) 2021-09-01
CN113347993A (zh) 2021-09-03
AU2019367965A1 (en) 2021-06-03
KR20210108944A (ko) 2021-09-03
MX2021004403A (es) 2021-10-22

Similar Documents

Publication Publication Date Title
JP2022508942A (ja) 変異ワクシニア・ウイルスおよびその使用
JP6422134B2 (ja) キメラ抗原受容体
CN108018299B (zh) 靶向bcma的嵌合抗原受体及其用途
CN105949324B (zh) 靶向gpc3的嵌合抗原受体及其用途
KR20200023165A (ko) 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용
CN108504668A (zh) 靶向cd19和cd22嵌合抗原受体及其用途
CN108004259B (zh) 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108070607A (zh) 靶向CD19-41BB-tEGFR的嵌合抗原受体及其用途
JP7437705B2 (ja) 抗ｃｄ３８及び抗ｃｄ１３８キメラ抗原受容体を含むｔ細胞、及びその用途
CN106999552A (zh) 治疗癌症的方法和组合物
CN107964549A (zh) 靶向cd22的嵌合抗原受体及其用途
CN110157679B (zh) 一种靶向性t淋巴细胞及其制备方法和应用
JP2021518126A (ja) 改変腫瘍溶解性アデノウイルス
CN108395478A (zh) 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
CN116348496A (zh) Bcma嵌合抗原受体
CN108070608A (zh) 靶向CD19-CD28-tEGFR的嵌合抗原受体及其用途
KR20190015544A (ko) 변형된 당단백질 d를 갖는 헤르페스 바이러스
CN107868792A (zh) 靶向cd123的嵌合抗原受体及其用途
CN108342360A (zh) 共表达抗msln嵌合抗原受体和无功能egfr的转基因淋巴细胞及其用途
CN116133671A (zh) 重组牛痘病毒
WO2021071534A1 (en) Mutant vaccinia viruses and use thereof
CN108285489A (zh) 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN110157675B (zh) 一种靶向性t淋巴细胞及其制备方法和应用
WO2019128996A1 (zh) 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN107556386A (zh) 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240515